中国临床药理学与治疗学2012，Vol.17Issue(5)：554-558,5.
吉西他滨联合洛铂或顺铂治疗蒽环类和紫杉类药物耐药晚期乳腺癌的比较研究
Comparison of GL (Gemicitabine plus Lobaplatin) and GP(Gemicitabine plus Cisplatin) in the treatment of metastatic breast cancer patients with anthracycline and taxane resistance
郝吉庆 1马强 1刘彭坤1
作者信息
- 1. 安徽医科大学第一附属医院肿瘤内科,合肥230022,安徽
- 折叠
摘要
Abstract
AIM: To evaluate the efficacy and adverse reactions of Gemicitabine / Lobaplatin (GL regimen) and Gemicitabine / Cisplatin ( GP regimen) in the treatment of metastatic breast cancer patients with anthracycline and taxane resistance. METHODS: A total of sixty-one patients with metastatic breast cancer were randomly assigned to receive the regimen of GL (n = 30) or GP (n = 31). GL regimen: Gemicitabine 1000 mg /m2 by infusion on dl,d8, Lobaplatin 30 mg /m2 on dl. GP regimen: Gemicitabine 1000 mg /m2 by infusion on dl ,d8,Cispla-tin 25 mg /m2 by infusion on dl — 3. All the patients had failures and relapse after previous treatment with anthracycline and taxane. Twenty-one days was a cycle in the both two groups. Every patient was administered at least 2 cycles. RESULTS:The overall response rate(CR+PR) was 43. 33% in GL regimen group and 38. 71% in GP regimen group (P>0. 05 ). The median time to progression (mTTP) in group GL and
GP was 6.29 months and 5.59 months (P > 0. 05). There were more neutropenia and throm-bocytopenia in the group GL, and more nausea and vomiting in the group GP. There were significant differences between the two groups(P< 0. 05). CONCLUSION, Both GL regimen and GP regimen are well effective for patients with anthracycline and taxane resistant metastatic breast cancer. And the response rate, median time to tumor progression were similar in both groups. The reaction of hematologic toxicity in the group GL was obviously higher than the group GP,but the gastrointestinal tract reaction was obviously higher in the group GP than the group GL. The two schemes may be suitable for different groups of people. And it is worthy of further clinical study.关键词
吉西他滨/洛铂/顺铂/转移性乳腺癌Key words
Gemicitabine/ Lobaplatin Cisplatin/ Metastatic breast cancer分类
医药卫生引用本文复制引用
郝吉庆,马强,刘彭坤..吉西他滨联合洛铂或顺铂治疗蒽环类和紫杉类药物耐药晚期乳腺癌的比较研究[J].中国临床药理学与治疗学,2012,17(5):554-558,5.
